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Abstract: Primary plasma cell leukemia (pPCL) is a rare and aggressive variant of 
multiple myeloma (MM) which may represent a valid model for high-risk MM. This 
disease is associated with a very poor prognosis, and unfortunately, it has not significantly 
improved during the last three decades. New high-throughput technologies have allowed  
a better understanding of the molecular basis of this disease and moved toward risk 
stratification, providing insights for targeted therapy studies. This knowledge, added to the 
pharmacogenetic profile of new and old agents in the analysis of efficacy and safety, could 
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contribute to help clinical decisions move toward a precision medicine and a better clinical 
outcome for these patients. In this review, we describe the available literature concerning 
the genomic characterization and pharmacogenetics of plasma cell leukemia (PCL). 
Keywords: plasma cell leukemia; molecular profiling; risk stratification; pharmacogenetics; 
precision medicine 
 
1. Introduction 
Plasma cell leukemia (PCL) is a rare and very aggressive variant of multiple myeloma (MM) 
defined by the presence of more than 20% of plasma cells (PC) in peripheral blood and/or an absolute 
PC count ≥2 × 109/L [1,2]. In MM, malignant PCs are tightly dependent on the bone marrow 
microenvironment, which is essential for their growth and survival; however, myeloma cells increase 
their ability to spread to peripheral blood (PB) and extramedullary sites during the course of this 
disease [2]. This dissemination to PB is caused by different expression of adhesion molecules and 
chemokine receptors sustained by several molecular aberrations [3]. PCL is classified as primary 
(pPCL) when it presents de novo in patients with no evidence of previous MM, or secondary (sPCL) 
when it is observed as a leukemic transformation in relapsed or refractory MM patients [1].  
The incidence of PCL in Europe is estimated around 0.04 cases per 100,000 persons per year, with a 
range of 2%–4% of patients with MM. Of this small percentage, 50%–70% of PCL are primary and the 
remaining are secondary forms [4–6]. 
pPCL patients show distinctive clinical-biological features if compared with MM or sPCL. They 
have a younger age at presentation and, compared to MM patients, are characterized by more frequent 
extramedullary disease and renal failure, higher bone marrow infiltration and proliferative activity of 
the malignant clone, and a low occurrence of bone disease [1,7]. Generally, pPCL may be initially 
sensitive to aggressive chemotherapy (especially to transplant procedures), but due to its aggressiveness, 
it almost invariably relapses early and, overall, clinical outcome is very poor. sPCL, on the other hand, 
represents the refractory end-stage of MM with survival measured in weeks [4,7]. 
In pPCL, multiple adverse genetic abnormalities are already present at the time of onset or 
diagnosis, whereas in sPCL they may gradually accumulate during progression from a previous  
MM phase, resulting in the acquisition of a more aggressive phenotype [8]. New high-throughput 
technologies have allowed a better understanding of the mechanisms underlying the biology of 
aggressive PC dyscrasias. As in many other cancers, biological information at diagnosis could be helpful 
for a prognostic risk stratification of this disease, which can guide clinicians in therapeutic decisions. 
During the last years, immunomodulatory drugs (thalidomide and lenalidomide) and the proteasome 
inhibitor bortezomib have undoubtedly modified the therapeutic scenario of MM, improving  
response rate, progression-free survival (PFS) and overall survival (OS). These agents are 
progressively getting into the treatment of pPCL [7]. Due to the low incidence and prevalence of PCL, 
most information about the efficacy and safety of these drugs in pPCL, as well as clinical-biological 
and genomic data, come from isolated case reports and small retrospective studies [9]. Only one 
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prospective study has been published until now and many of the genomic analyses in consideration 
during this review come from this prospective series [10]. 
Here, we discuss the genomic characteristics of pPCLs based on conventional approaches,  
such as karyotype and fluorescence in situ hybridization (FISH) analyses, and more recent, new  
high-throughput technologies such as single nucleotide polymorphism (SNP)-array, gene expression 
profiling (GEP), miRNA expression profiling, and whole exome sequencing (WES). We also 
summarize findings about the efficacy and safety variability related to genetic variations for old  
and new therapeutic regimens currently used for PCL treatment. We conclude that the development  
of biomarker discovery and improvement of pharmacogenomics knowledge by new genomic 
technologies may lead to a better clinical outcome of this rare and aggressive tumor. 
2. Molecular Classification and Prognostic Risk Stratification 
Genomic characterization from previously published retrospective series of PCLs, mainly based on 
conventional karyotyping, FISH, and array comparative genomic hybridization (aCGH) analyses, 
indicated a scenario of major genetic lesions that can overlap those found in MM, although PCLs have 
several specific features [4,11]. The percentage of PCL patients with an abnormal clone detectable by 
cytogenetic analysis is significantly higher than in MM [12,13]. From this data it is possible to infer 
that clonal PC from PCL, as said before, has a higher proliferative capacity and cell turnover when 
compared with MM [13]. 
Different data and percentages were reported in past retrospective studies, mainly due to the 
difficulty of recruiting a valid and representative number of patients with this rare disease. In the paper 
by Chiecchio et al. [13], the majority of pPCLs (7/10; 70%) were non-hyperdiploid (non-HRD), while 
a HRD karyotype was evidenced in the remaining pPCLs and in one out of two sPCLs. In the data 
reported by Tiedemann et al. [4], all investigated pPCLs were exclusively non-HRD, and HRD  
was found only in sPCLs. With regard to chromosomal translocations, involving the immunoglobulin 
heavy-chain locus (IGH@) at 14q32, they have been frequently found in pPCL and sPCL patients 
(82%–87%). Data from retrospective studies indicated that the Cyclin D1 (CCND1) gene, on locus 
11q13, was mostly targeted in pPCL, while 14q32 rearrangements targeting 4p16.3 (Fibroblast growth 
factor receptor 3—FGFR3 and Multiple Myeloma SET domain—MMSET) or 16q23 (MAF) occurred 
more frequently in sPCL [2,4]. 
In particular, Chang et al. [14] observed t(11;14) and t(4;14) chromosomal translocations in four 
(50%) and three (25%) pPCL patients, respectively. This is in agreement with data from  
Avet-Loiseau et al. [15], showing a higher frequency of 33% for t(11;14) in comparison to 13% for 
t(4;14), and Chiecchio et al. [13], who reported t(11;14) in 40% of pPCL patients and the absence of 
t(4;14). Furthermore, a different prognostic significance was associated with these chromosomal 
aberrations, with a better overall survival (OS) associated with t(11;14) reported by Avet-Loiseau et al. [15] 
but not by Chiecchio et al. [13], while Chang et al. [16] showed t(4;14) as an independent predictor for 
a poor OS. 
Chang et al. [16] reported that 17p and 13q deletions were more frequent in PCL than in MM. 
Furthermore, the presence of del(17p) and del(13q) was associated with shorter OS [9]. TP53 
inactivation, in addition to 17p deletion, can be caused by functionally mono- or bi-allelic coding 
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mutations. Moreover, inactivation of TP53 can also happen by overexpression of negative regulatory 
elements, such as mouse double minute 2 homolog (MDM2), or by decreased activity of CDKN2A 
(p14ARF), a negative regulator of MDM2 [17,18]. Damaging of TP53 surveillance can induce genetic 
instability with the development of complex genetic abnormalities, and may be a prerequisite for 
dysregulation of oncogenes such as RAS and MYC [4]. 
1q gains and 1p losses are more frequent in PCL and both aberrations are strongly correlated. 
Importantly, 1p deletions, but not 1q gains, appear associated with a shorter survival [16]. 
Mutations of K-RAS or N-RAS (at codons 12, 13, or 61) have been reported in a retrospective series 
in 27% of pPCLs and 15% of sPCLs [4]. The prevalence of these mutations in sPCL was similar to that 
described in MM (21%) [1,19]. Rearrangements of MYC (as 3ʹ FISH break apart) were evidenced in 33% 
of pPCL and sPCL tumors, in addition to amplification or 5ʹ translocations in 8% and 17% of patients, 
respectively, and were found associated with poorer OS in pPCL [4]. Even in the study by  
Chiecchio et al. [13], highly variable structural and numerical alterations were found affecting  
MYC, leading to increasing levels of MYC transcript, particularly in relation to the type of  
genomic abnormality. 
Finally, Usmani et al. [20] examined differences in transcriptional profiles of pPCL in comparison 
to non-pPCL cases, including MM, sPCL, and human myeloma cell lines. Data from this study suggest 
that pPCL samples represent a well-defined molecular entity that is distinguished from non-pPCL cases by 
a 203 gene-signature, involving transcripts mainly concerned in the lipid-metabolism pathway. 
Despite the number of studies and the attempts to characterize this disease, a comprehensive 
analysis of genomic aberrations and the application of other “omics” technologies are still lacking in 
prospective series of pPCL. Recently, our groups have provided an extensive biological and molecular 
characterization of a panel of 23 pPCLs included in a Phase II prospective trial, aiming to evaluate the 
efficacy of novel biological drugs (lenalidomide in combination with dexamethasone) in the treatment 
of pPCL [10] (Table 1). 
Mosca et al. [21] provided a detailed genomic characterization of this prospective series by 
integrating SNP-array and FISH data with the corresponding transcriptome profiles. IGH@ 
translocations were identified in 87% of pPCL patients, with the most prevalence of t(11;14) (39%) 
and t(14;16) (30%). Meanwhile, the most frequent numerical alterations involved 1p (38%), 1q (48%),  
6q (29%), 8p (42%), 13q (74%), 14q (71%), 16q (53%), and 17p (35%). They identified mutations of 
TP53 in four cases, whereas activating mutations of the BRAF oncogene occurred in one case, while 
they were totally absent in N- and K-RAS. Furthermore, functional clustering analysis on differentially 
expressed genes mapped within altered copy number regions showed that the deregulated genes were 
mostly involved in processes fundamental for cancer development, such as intracellular protein 
transport, and Wnt and NF-kappa (NF-κB) pathways. In addition, several transcripts both in gained 
(PSMB4, PSMD4, UCHL5) and deleted (PPP2CB, PPP2R5C, PSMC6, PSMD7) chromosomal regions 
were associated with proteasomal ubiquitin-dependent protein catabolic process. Figure 1A shows the 
reported frequency of the major genetic alterations in our prospective pPCL series compared to other 
retrospective cohorts. As shown, the frequency of the main IGH@ translocations is variable in the 
different PCL series. For example, t(11;14) represents 39% of our population, which is close to that 
reported by Avet-Loiseau et al. [15] (33%) and Chiecchio et al. [13] (40%), but different from 
Tiedemann et al.’s series [4] (65%). MAF translocations were evidenced in 38% of pPCLs in our 
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series, comparable to the 30% reported by Chiecchio et al. [13], whereas they were totally absent in 
Tiedemann et al.’s series [4]. Figure 1B shows the frequencies of the major genomic alterations in the 
prospective pPCL series compared to a proprietary retrospective cohort of newly diagnosed MM 
patients and sPCL cases [22]. As shown, the overall frequency of the major genetic alterations in PCL, 
in particular the 17p deletion, is higher than that found in MM. 
Table 1. High-throughput technologies in pPCL classification. 
Reference 
pPCL 
Patients 
Molecular 
Classification 
Integrated 
Analysis 
Gene/miRNA 
Signature 
(pPCL vs. MM) 
Clinical Outcome 
Signature 
Gene/miRNA List 
Usmani  
et al.,  
2012 [20] 
13 GEP - 203 DE genes  - - 
Mosca L. 
et al.,  
2013 [21] 
23 FISH 
GEP - - - 
17 SNP-array 
Todoerti  
et al., 
2013 [23] 
21 GEP - 503 DE genes  
3 genes-response 
rate 
YIPF6, EDEM3, 
YB5D2 
27 genes-OS 
PECAM1, MKX, 
FAM111B, MCTP1, 
CALCRL, C10orf10, 
FNBP1, EFEMP1, 
C3orf14, ALDH1L2, 
WARS, SLC15A2, 
FAIM3, CPEB4, 
EDN1, PVALB, 
LY86, LAPTM5, 
RNU5D, PARP15, 
PLEKHF2, PDK4, 
TNFAIP3, 
FAM105A, CTH, 
HOOK1, TCN2 
Lionetti  
et al., 
2013 [24] 
18 miRNA 
SNP-array/
GEP 
83 DE miRNAs 
4 miRNAs-treatment 
response 
miR-106b, miR-497, 
miR-181b, miR-181a 
4 miRNAs-PFS/OS 
miR-92a, miR-330-3p, 
miR-22, miR-146a 
Cifola  
et al., 
2015 [25] 
12 WES 
SNP-array/
GEP 
- - - 
DE—differentially expressed; GEP—gene expression profiling; FISH—fluorescence in situ hybridization; 
SNP—single nucleotide polymorphism; OS—overall survival; PFS—progression free survival; WES—whole 
exome sequencing. 
Concerning the transcriptomic profiles, Todoerti et al. [23] investigated the gene expression profiles 
of 21 pPCL patients of the same series by means of microarray technology, correlating them with the 
primary and secondary outcome endpoints. As in MM, the main IGH@ chromosomal translocations 
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drive the clustering of pPCL patients and are associated with specific transcriptional signatures. 
Interestingly, the combined analysis of 21 pPCLs and 55 newly diagnosed MM cases clustered 
together both PC dyscrasia samples in the main IGH@ translocation groups, thus suggesting that the 
presence of these chromosomal translocations, rather than the specific disease, strongly affects the 
transcriptional profiles in pPCL. Indeed, a 503-gene signature was able to distinguish pPCL from MM, 
highlighting the involvement of cytoskeleton functions, Rho protein signalling, and NF-κB pathways. 
Only a small overlapping (15%) with the GEP signature reported by Usmani et al. [20] in pPCL 
compared to non-pPCL samples was observed. 
Furthermore, 26 genes of the identified transcriptional signature showed an expression trend 
associated with disease progression from normal PC condition throughout PCL. Finally, the expression 
levels of three genes (CYB5D2, EDEM3, and YIPF6) were correlated with response to the first-line 
treatment with lenalidomide/dexamethasone and a specific signature of 27 genes, resulting mostly  
up-regulated (17/27, 63%) in the pPCL patients with the poorest outcome, was associated with OS. 
Notably, the identified 27-gene model was independently associated with OS after adjustment for 
major cytogenetic alterations and hematological parameters. Importantly, the identified 27-gene 
signature retained significant correlation with outcome against known gene-risk models in MM, which 
stratify high- and low-risk myeloma patients on the basis of gene expression profile (UAMS 70-gene 
and 17-gene [26]; IFM 15-gene [27] and UK 6-gene [28]) [23]. On the other hand, the low-risk 
signature was found strongly associated with the autologous stem cell transplantation (ASCT) 
procedure and, consequently, with a more favorable prognosis. 
MicroRNAs are short non-coding RNAs that control cell functions through mRNA targeting. 
Recently, abnormal expression of miRNAs has been reported in most of the solid or hematopoietic 
malignancies, including MM [29,30], and several preclinical findings have demonstrated their broad 
anti-cancer activity in the disease [31]. A global miRNA expression profiling was performed by 
microarray analysis in 18 pPCLs of the same series by Lionetti et al. [24]. A specific pattern of 
differentially regulated miRNAs (42 up-regulated and 41 down-regulated) was identified in pPCL 
when compared with a representative series of 39 MM. Interestingly, up-regulated miRNAs in pPCL 
were enriched in “onco-miRNAs”, such as miR-21 and miR-155, and recognized in miR-17~92 and 
miR-106a~363 clusters (miR-18a, miR-19a, miR-18b, and miR-20b). Interestingly, the expression of 
some miRNAs was associated with the DNA copy number of the corresponding loci, such as 
chromosomes 13 and 1. Finally, four miRNAs (miR-497, miR-106b, miR-181a, and miR-181b) were 
correlated with treatment response, and four (miR-92a, miR-330-3p, miR-22, and miR-146a) with 
clinical outcome. Among others, miR-146a and miR-22 deserve some attention. MiR-146a plays an 
important role in the regulation of innate immune and inflammatory responses through a negative 
feedback pathway involving NF-κB [32] and has been associated with the pathogenesis of several 
human diseases, whereas miR-22 was found significantly down-regulated in agreement with the allelic 
loss of its locus at 17p13.3 [33]. 
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Figure 1. (a) Percentage of main genetic alterations in primary plasma cell leukemia 
(pPCL) patients of our prospective series compared to other retrospective pPCL cohorts; 
(b) Percentage of the same genetic lesions in the proprietary dataset of 132 multiple 
myeloma (MM) patients at onset, 24 pPCL and 11 secondary plasma cell leukemia  
(sPCL) cases (elaborated from Lionetti et al., Oncotarget 2015 [22]). Main chromosomal 
translocations, involving the immunoglobulin heavy-chain locus (IgH@) at 14q32 as 
t(4;14), t(11;14), MAF-translocations (trx), chromosome 13 and 17 deletions (del(13q), 
del(17p)), and chromosome 1 gains and losses (1q gain, 1p loss) are depicted. 
Finally, to provide knowledge about the mutational profile of this disease, Cifola et al. [25] 
performed WES analysis of 12 pPCL cases included in the same prospective trial. They identified 
1928 coding somatic non-silent variants on a total 1643 genes, with a mean of 166 variants per sample. 
Interestingly, few variants and genes were recurrent in two or more samples. They were able to 
identify 14 candidate cancer driver genes involved in cell-matrix adhesion, cell cycle, genome 
stability, RNA metabolism, and protein folding. Furthermore, the integration of mutation data with the 
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copy number alteration profiles revealed biallelically disrupted genes with tumor suppressor functions. 
Globally, cadherin/Wnt signaling, the extracellular matrix, and cell cycle checkpoints were the most 
affected functional pathways. Furthermore, Cifola et al. [25] reported a marked involvement of the  
TP53 gene, with a recurrent implication of the ATM and ATR genes: two checkpoint kinases required 
for cell cycle arrest and DNA damage repair activation. The co-occurrence of mutations in different 
members of the DNA damage response, such as TP53, ATM, ATR, CHEK2, CDC25A, CDKN1A, 
BRCA1, may suggest a potential synergic role in deregulated DNA repair function in pPCL. This  
study represents the first WES analysis of pPCL and indicates a remarkable genetic heterogeneity  
of mutational patterns. Moreover, concerning the mutational status of genes recognized in the  
mitogen-activated protein kinase (MAPK) signaling, such as BRAF, NRAS, and KRAS, more recently,  
Lionetti et al. [22] have demonstrated, in a large panel of 167 patients representative of the different 
forms of PC dyscrasias (132 MM, 24 pPCL, and 11 sPCL), that mutations were found in 12% (BRAF), 
23.9% (NRAS), and 29.3% (KRAS) of cases, respectively. Overall, mutations involving all three genes 
occurred in 63.6% of sPCL, 59.8% of MM, and 41.7% of pPCL cases [22]. 
3. Pharmacogenetics of New and Old Agents: Adverse Drug Reaction and Efficacy 
Characterization of tumor genomics can help physicians to determine a patient’s disease and 
therefore the treatment choice. Nevertheless, the study of germline genetic variations, known as 
pharmacogenetics, can define kinetics and dynamics of cancer therapy pharmacology [34], establishing 
the variability of efficacy and safety and guiding physicians to the best drug and dosage. 
Due to the complexity and rarity of PCL, information about efficacy and safety of therapy is poor 
and is mainly based on single case reports and small retrospective series with few patients. There is no 
pharmacogenetic information deriving directly from PCL patients; knowledge about pharmacology of old 
and new drugs used in treatment is based mostly on MM [35], which has a similar therapeutic regimen. 
For this reason, we reviewed available information about new and old regimens used in  
PCL treatment. Terms used for the search on PubMed were “name of drug”, “multiple myeloma or 
plasma cell leukemia”, and “pharmacogenetics or pharmacogenomics or polymorphisms”. 
Furthermore, we analyzed information on “The Pharmacogenomics Knowledgebase” (PharmGKB) [36], a 
manually curated database of pharmacogenetic variation, looking for associations with other diseases. 
We discussed information about old and new drugs used in MM (Table 2) and reported in Supplementary 
Table S1 all the clinical information on other diseases derived from PharmGKB analyses. 
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Table 2. Germline genetic variations and efficacy/safety of old and new drugs used in the 
treatment of PCL and MM. 
Drug Gene SNP Alleles 
Amino Acid 
Translation 
Annotation Reference 
Melphalan 
ERCC2 rs13181 T>G 
Lys751Gln 
or K751Q longer time to  
treatment failure 
Vangsted et al., 
2007 [37] 
XRCC3 rs861539 G>A 
Thr241Met 
T241M 
ALDH2 
rs440 T>C - 
response to HDM 
Dumontet et al., 
2010 [38] 
rs4646777 G>A - 
GSTT2 rs1622002 G>A Met139Ile 
BRCA1 
rs799917 
C>G;  
C>T;  
C>A 
Pro824Gln; 
Pro824Leu 
rs4986850 
G>A;  
G>T;  
G>C 
Asp646Tyr; 
Asp646Asn 
CYP1A1 rs1048943 
T>G;  
T>C;  
T>A 
Ile462Val; 
Ile462Leu; 
Ile462Phe 
disease progression 
RAD51 rs1801320 G>C - 
PARP4 rs13428 
G>A;  
G>C 
Gly1280Arg; 
Gly1280Cys 
ALDH2 rs886205 A>G - 
OS 
CYP1A1 rs1048943 
T>G;  
T>C;  
T>A 
Ile462Val; 
Ile462Leu; 
Ile462Phe 
BRCA1 rs4986850 
G>A;  
G>T;  
G>C 
Asp646Tyr; 
Asp646Asn severe mucositis  
after HDM  
CDKN1A rs1801270 C>A Ser31Arg 
XRCC1 rs25487 T>C Gln399Arg 
SLC7A5 rs4240803 G>A - 
gastrointestinal side 
effects 
Giglia et al., 
2014 [39] 
IL-1β rs1143627 -31 C/T - OS Vangsted et al., 
2009 [40] 
Vincristine 
GLI1 
rs2228224 G>A Gly892Asp early-onset peripheral 
neuropathy Broyl et al., 
2010 [41] 
rs2242578 G>C - 
DPYD rs1413239 C>T - late-onset peripheral 
neuropathy ABCC1 rs3887412 A>C - 
GSTP1 rs1695 A>G Ile105Val 
response after 
chemotherapy 
Maggini et al., 
2008 [42] 
TYMS or 
ENOSF1 
rs2790 
A>T; 
A>G 
- 
rs699517 C>T - response after SCT 
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Table 2. Cont. 
Drug Gene SNP Alleles 
Amino Acid 
Translation 
Annotation Reference 
Dexamethasone 
MRD1 or 
ABCB1 
rs2032582 
A>T;  
A>C 
Ser893Ala; 
Ser893;Thr 
OS 
Maggini et al., 
2008 [43] 
rs1045642 
A>T;  
A>G 
Ile1145Ile 
GSTP1 rs1695 A>G Ile105Val 
response after 
chemotherapy 
Maggini et al., 
2008 [42] 
TYMS or 
ENOSF1 
rs2790 
A>T; 
A>G 
- 
rs699517 C>T - response after SCT 
Bortezomib 
NFKB1 rs28362491 
ATTG> 
del 
- PFS 
Varga et al., 
2015 [44] 
TRAF3 rs11160707 G>A - PFS 
Du et al.,  
2011 [45] 
NFKB2 rs12769316 G>A - OS 
PSD rs1056890 G>A - OS 
MRP1 or 
ABCC1 
rs4148356 G>A Arg723Gln PFS-OS 
Buda et al.,  
2010 [46] 
CASP9 
rs2020895 A>G - 
early-onset peripheral 
neuropathy  
Broyl et al., 
2010 [41] 
rs2020903 G>A - 
rs4646034 T>C - 
ALOX12 
rs1126667 A>G Gln261Arg 
rs434473 A>G Asn322Ser 
IGF1R rs1879612 T>C - 
ERCC4 
rs1799800 G>A - 
late-onset peripheral 
neuropathy 
rs1799801 T>C Ser835Ser 
ERCC3 rs2276583 G>A - 
PPARD rs2267668 G>A - 
CTLA4 rs4553808 A>G - 
peripheral neuropathy  
Favis et al., 
2011 [47] 
CTSS rs12568757 G>A - 
PSMB1 rs1474642 A>G - 
TCF4 rs1261134 A>T - 
DYNC1I1 rs916758 A>G - 
Thalidomide 
ABCA1 rs363717 C>T - 
peripheral neuropathy  
Johnson et al., 
2011 [48]  
ICAM1 rs1799969 G>A Gly241Arg 
PPARD rs2076169 A>G - 
SERPINB2 rs6103 C>G Asn404Lys 
SLC12A6 rs7164902 
C>G;  
C>A 
Leu144Leu 
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Table 2. Cont. 
Drug Gene SNP Alleles 
Amino Acid 
Translation 
Annotation Reference 
Thalidomide 
ERCC1 or 
CD3EAP 
rs735482 A>C Lys259Thr 
response rate 
Cibeira et al., 
2011 [49] 
ERCC5 rs17655 G>C Asp1104His 
XRCC5 rs1051685 A>G - 
ERCC1 or 
CD3EAP 
rs735482 A>C Lys259Thr 
OS 
XRCC5 rs1051685 A>G - 
GSTT1 rs4630 G>A - peripheral neuropathy  
CDKN1A rs3829963 C>A - VTE 
Almasi et al., 
2011 [50] 
TNF-alpha rs361525 G>A - PFS-OS 
Du et al.,  
2010 [51] 
CYP2C19 Extensive metabolizers - OS 
Li et al.,  
2007 [52] 
Lenalidomide NFKB1 rs3774968 A>G - VTE 
Bagratuni et al., 
2013 [53] 
HDM—high dose melphalan; OS—overall survival; PFS—progression free survival; VTE—venous 
thromboembolism; SCT—stem cell transplantation. 
3.1. Melphalan 
Melphalan has been the first drug with proper efficacy in MM and it still remains a master drug in 
these patients, especially in the context of autologous stem cell transplantation (ASCT) [54]. Anyway, 
there are few data about predictive factors of response to high-dose chemotherapy with melphalan 
(HDM) in MM patients or association with its severe side effects, such as mucositis, diarrhea, and 
myelosuppression [55]. 
Polymorphisms of genes involved in drug metabolism, DNA repair, and apoptosis have been 
studied and associated with different profiles of toxicity/efficacy in MM patients. In particular, the 
combination of the polymorphisms rs13181 in ERCC2 and rs861539 in XRCC3 was associated with a 
longer time to treatment failure [37]. In the study by Dumontet et al. [38], polymorphisms in ALDH2, 
GSTT2, and BRCA1 genes significantly influenced response to therapy; variants in CYP1A1, RAD51, 
and PARP were independently correlated with disease progression, whereas SNPs in ALDH2 and 
CYP1A1 were associated with death. Furthermore, polymorphisms in BRCA1, CDKN1A, and XRCC1 
were associated with a higher prevalence of severe side effect, particularly the occurrence of severe 
mucositis after HDM. Giglia et al. [39] conducted a study to investigate the association of melphalan 
therapy and gastrointestinal side effects. In particular, they investigated the principal mediators of 
melphalan uptake, the amino acid transporters LAT1 and LAT2, encoded by the SLC7A5 and SLC7A8 
genes, respectively. This study shows that a patient carrying rs4240803 in SLC7A5 had a higher 
requirement of total parenteral nutrition use. 
Interestingly, polymorphisms of genes coding for proinflammatory cytokines, suspected to play a 
role in the pathogenesis of MM, were investigated in 348 MM patients undergoing HDM treatment 
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followed by ASCT. Patients carrying the rs1143627 allelic variant in IL-1b showed a significantly 
longer survival than wild-type homozygous patients [40]. 
3.2. Vincristine 
Vincristine has been one of the most widely used and effective drugs in MM and PCL treatment, 
although the dose-limiting toxicity and an incomplete understanding of the pharmacokinetics and 
pharmacogenetics of vincristine may limit its current therapeutic potential. Induced peripheral 
neuropathy may be a dose-limiting toxicity. In early-onset, rs2228224 and rs2242578 SNPs in  
the GLI1 gene appeared to be associated with peripheral neuropathy. Late-onset was associated  
with polymorphisms in genes involved in drug metabolism, such as rs1413239 in DPYD and  
rs3887412 in ABCC1 [41]. 
Maggini et al. [42] studied the response to dexamethasone-doxorubicin-vincristine (DAV) therapy 
in MM patients associated with polymorphisms in genes of drug metabolism (GSTP1) and DNA 
synthesis (TYMS). These patients were treated with DAV followed by a conditioning regimen and 
ASCT. In particular, rs1695 in GSTP1 and rs2790 in TYMS were significantly associated with a poor 
response following chemotherapy. Interestingly, an increased risk was observed in patients carrying a 
combined genotype. Moreover, patients with rs699517 in TYMS showed a significantly poorer 
response after ASCT. 
3.3. Cyclophosphamide 
Due to the complex metabolism, this drug has been associated with a large number of genes and 
processes, such as hepatic CYP450 (CYP2A6, 2B6, 2C8, 2C9, 2C19, 3A4, and 3A5), NADPH-mediated 
oxidation by aldehyde dehydrogenases (ALDH1A1 and ALDH3A1), and conjugation with glutathione 
by glutathione S-transferases such as GSTA1, GSTM1, GSTP1, and GSTT1 [35,56]. 
3.4. Dexamethasone 
Maggini et al. [43] evaluated the effect of diplotypes of MDR1 (ABCB1) gene polymorphisms 
(rs1045642 and rs2032582 positions) on the clinical outcome of MM cases treated with the DAV 
regimen. These two single nucleotide polymorphisms are in strong linkage disequilibrium and the 
analyses showed that survival probability was lower in wild-type homozygous carriers for both SNPs 
(55%) than for variant carriers (in heterozygous or homozygous). As reported for vincristine,  
rs1695 in GSTP1 and rs2790 in TYMS were significantly associated with a poor response  
following chemotherapy [42]. 
3.5. Bortezomib 
The proteasome inhibitor bortezomib has shown multifactorial biological effects on both myeloma 
and microenvironment cells, such as suppression of adhesion molecule expression and inhibition of 
angiogenesis. The initial rationale to use bortezomib was its inhibitory effect on the NF-κB pathway, 
which is highly activated in MM [57]. Varga et al. [44] retrospectively analyzed the role of the 
rs28362491 NFKB1 polymorphism, an insertion/deletion variant, on the survival of 295 MM patients 
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treated with bortezomib. Interestingly, patients carrying homozygous insertion have a better 
progression-free survival from bortezomib treatment than patients with the insertion/deletion or 
homozygous deletion. Another study investigated 26 polymorphic sites of NF-κB family member 
genes (IKB-α, NFKB2, and TRAF3) in 83 MM patients. Notably, rs11160707 in the TRAF3 gene was 
significantly associated with a better PFS; patients with rs12769316 in NFKB2 had a superior OS, 
while rs1056890 was associated with an inferior OS. The authors concluded that at multivariate 
analysis, TRAF3 rs11160707 was an independent favorable factor for PFS [45]. 
Vangsted et al. [58] conducted a study on 348 patients undergoing HDM and ASCT, showing that 
carrying one or two defective CYP2D6 alleles can be predictive, albeit not statistically significant, of  
a trend towards a better time-to-next treatment. Even MDR1 and MRP1 genes, known as ABCC1, can 
modify the capacity to mediate drug resistance. Interestingly, Buda et al. [46] retrospectively evaluated 
the role of MRP1 and MDR1 on outcomes in relapsed and/or refractory MM patients in therapy  
with bortezomib and pegylated doxorubicin. The rs4148356 polymorphism in the MRP1 gene was 
associated with a longer PFS and OS. 
Bortezomib-induced peripheral neuropathy is a dose-limiting toxicity. This adverse event requires 
adjustment of therapy and can affect quality of life. The early onset of peripheral neuropathy in 
patients treated with bortezomib was significantly associated with SNPs in apoptosis genes, such as 
CASP9, ALOX12, and IGF1R; SNPs in inflammatory genes like MBL2 and PPARD, and ERCC3 and 
ERCC4 DNA repair genes, were statistically associated with late-onset neuropathy [41]. Furthermore, 
genes involved in immune response (CTLA4-rs4553808 and CTSS-rs12568757), drug binding 
(PSMB1-rs1474642), or with a functional role in the nervous system (TCF4-rs1261134 and  
DYNC1I1-rs916758) were associated with bortezomib-induced peripheral neuropathy [47]. 
3.6. Thalidomide 
Thalidomide has a complex mechanism of action that is not yet fully understood [59]. This drug 
undergoes a process of biotransformation, generating a multitude of metabolites and the genotype 
variation of the candidate genes involved in its metabolism can interfere with efficacy and safety 
during therapy. To identify genetic variations able to modulate and predict the risk of  
thalidomide-related peripheral neuropathy, Johnson et al. [48] analyzed samples from 1495 MM 
patients. They reported associations with SNPs in ABCA1 (rs363717), ICAM1 (rs1799969), PPARD 
(rs2076169), SERPINB2 (rs6103), and SLC12A6 (rs7164902) genes. These data are supported by the 
hypothesis that genes that have a role in inflammation and repairing mechanisms of the peripheral 
nervous system may influence the risk of developing peripheral neuropathy after treatment [60]. 
Cibeira et al. [49] examined polymorphisms in genes involved in multidrug resistance, drug 
metabolic pathways, DNA repair systems, and cytokines in 28 relapsed/refractory MM patients treated 
with thalidomide as a single agent. Patients carrying SNPs in ERCC1 (rs735482), ERCC5 (rs17655), or 
XRCC5 (rs1051685) showed a higher response rate to therapy. Specifically, polymorphisms in ERCC1 
(rs735482) and XRCC5 (rs1051685) were associated with longer OS. Indeed, patients showing rs4630 
in GSTT1 had a lower frequency of induced peripheral neuropathy. Additionally, Almasi et al. [50] 
analyzed the risk of venous thromboembolism (VTE), a well-known adverse event of thalidomide 
treatment, in 111 retrospective MM patients. Particularly, MM cases with rs3829963 in the CDKN1A 
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gene had a higher frequency of VTE compared with the wild-type genotype. Du et al. [51] tested the 
impact of TNF-alpha promoter polymorphisms on the clinical outcome. They analyzed 98 MM patients 
treated with the thalidomide and dexamethasone regimen. The TNF-alpha rs361525 polymorphism was 
associated with better PFS and OS, confirming a previous independent study on 81 refractory MMs [61]. 
Furthermore, the role of CYP2C19 polymorphisms (CYP2C19*2-rs4244285, CYP2C19*3-rs4986893) 
was investigated in 92 MM cases, 62 of which were treated with thalidomide and dexamethasone and 
30 of which were treated with thalidomide combined with chemotherapy. CYP2C19 extensive 
metabolizers had a higher and statistically significant overall response rate when compared to poor 
metabolizer patients carrying the CYP2C19*2 or *3 variants [52]. 
3.7. Lenalidomide 
The antiangiogenic and immunomodulatory properties of lenalidomide have been associated with 
notable efficacy in newly diagnosed and relapsed/refractory MM patients [62]. Unfortunately, 
lenalidomide is associated with a significant risk of VTE. Bagratuni et al. [53] analyzed 200 MM 
patients in therapy with lenalidomide-based regimens, showing that, in patients that received low-dose 
aspirin as prophylaxis, rs3774968 in the NFKB1 gene was associated with an increased risk of VTE. 
4. Conclusions 
PCL represents a unique subset of patients with an aggressive clinical presentation, poor prognosis, 
shorter survival, and a different biologic background compared to MM [1]. Several studies 
demonstrated that the intensive treatment, introduction of novel agents such as lenalidomide and 
bortezomib, and bone marrow transplantation (allogenic and autologous stem cell) improved the 
survival of PCL patients [2,5,7]. Unfortunately, survival is still inferior if compared with the outcome 
in newly diagnosed MM patients, indicating the necessity for novel treatment strategies [3]. PCL 
patients should be considered primary beneficiaries for the newer novel agents, alone or in 
combination, such as second-generation proteasome inhibitors (Carfilzomib, Ixazomib), third-generation 
immunomodulatory drugs (Pomalidomide), and monoclonal antibodies (Elotuzumab, Daratumumab), 
as well as inhibitors of histone deacetylase, Akt, or mTOR [3,62–65]. 
Besides pharmacological research, improved genomic classification can help us in distinguishing 
groups of patients that may differ not only at the time of diagnosis but also in how they evolve or 
become resistant [66–68]. Data derived from the only study involving a pPCL prospective  
series [10,21,23,24] provided an in-depth scenario of genomic alterations in pPCL, although it should 
be taken into account that the difference between these data with others previously published [4,20] may 
be due to the relatively small number of cases and thus to the heterogeneity of all the series investigated, 
the geographical factors, or the methodology used to screen samples (see Figure 1). Furthermore, the 
identified transcriptional profile distinguishing pPCL from MM in the proprietary series showed only a 
small overlapping with the Usmani gene signature [20], probably due to different generation arrays or 
the molecular stratification of pPCL and MM/non-pPCL samples used in GEP comparisons. 
We have recently proposed, in our prospective PCL cohort [23], a gene model related to clinical 
outcome; specifically, three genes were associated with response rate and 27 genes were associated 
with OS, retaining independence in OS prediction with respect to several known gene-risk models 
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described in MM [23]. This finding requires more studies and consensus in order to define a reduced 
and powerful signature for prognostic stratification [69]. Similarly, Lionetti et al. [24] defined a 
miRNA signature highlighting the role of these small non-coding RNAs in pPCL, also as possible 
novel therapeutic targets. As for the gene signature, a larger prospective series is required to better 
understand the clinical significance of miRNAs. 
Next-generation sequencing (NGS) might shed new light in the genetic complexity of pPCL.  
Cifola et al. [25] showed the involvement of a disparate set of genes and pathways useful as actionable 
targets. This first WES study on prospective pPCL patients can open new scenarios, improving the 
existing therapeutic opportunity. 
Furthermore, molecular and genomic variability can have a great effect on drug efficacy and 
toxicity. Unfortunately, we still lack knowledge about the mode of action of many new drugs and  
how they interact with more than one target gene/protein [66,70]. Some of the genes, mentioned in 
pharmacogenetic studies, suggest the involvement of common pathways such as DNA damage 
response and nucleotide excision repair (RAD51, BRCA1, ERCCs, and XRCCs genes), Receptor 
Activator of Nuclear Factor kappa-B (RANK) RANK ligand (RANKL) signaling, apoptosis, and the 
NF-κB pathway (TRAF3, NFKB2, ICAM1, IGF1R, NFKB1, CASP9), together with genes concerned in 
cytochrome P450 and glutathione metabolism (see Supplementary Figure S1, performed using 
GeneMANIA) [71]. At present, there is little and controversial information about their clinical 
relevance. In addition, the mechanisms of their side effects are not fully understood. The success of a 
cancer therapy depends also on dose-limiting toxicity that can compromise the patient’s quality of life. 
The potentiality to stratify patient treatment according to genetic risk factors associated with adverse 
events is really important, but large prospective clinical studies are needed before the introduction in 
clinical practice [34,35,66,67]. It is well known that PCL has a poor prognosis, but the possibility of 
selecting patients with a more favorable outcome, thus avoiding them having adverse drug reactions, 
could be a great advantage. 
The completion of the human genome project in 2003 and the use of “omics” technologies, such as 
microarray and NGS, has allowed medical research to progressively identify and improve the use of 
biomarkers in clinical practice. This process is intended to grow in parallel with our ability to 
understand genomic data and the improvement in “omics” technologies in terms of cost- and  
time-efficiency [72]. The ability to integrate these data with clinical information is crucial and will be 
one of the main purposes of precision medicine [72]. Up until now, many biomarkers failed in the 
process that led to success and to clinical implementation [73], mainly due to difficulty in 
independently replicating findings or in defining an exact event of adverse drug reaction. In a disease 
like PCL, with a small number of available cases, this risk becomes much more important. 
Enrollment in large, collaborative, and well-organized clinical trials will thus become particularly 
important, expecting to have access to electronic healthcare and “omics” databases where patients can 
be followed longitudinally from the time of diagnosis to the clinical outcome [66–68]. Even as a 
“niche” disease with a set of problems with large enrollment and prospective validations, PCL could 
represent a valid model for precision medicine due to the necessity to decide on the treatment with the 
best efficacy/toxicity ratio for each patient as fast as possible. 
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